title: Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
abstract: Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.
authors.affiliation: a Department of Leukemia , The University of Texas M. D. Anderson Cancer Center , Houston , Texas , USA.
authors.forename: Naval
authors.initials: N
authors.lastname: Daver
authors.affiliation: a Department of Leukemia , The University of Texas M. D. Anderson Cancer Center , Houston , Texas , USA.
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.affiliation: a Department of Leukemia , The University of Texas M. D. Anderson Cancer Center , Houston , Texas , USA.
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.affiliation: a Department of Leukemia , The University of Texas M. D. Anderson Cancer Center , Houston , Texas , USA.
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
mesh_terms: D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D016879:Salvage Therapy; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D007521:Isocitrate Dehydrogenase; D051941:fms-Like Tyrosine Kinase 3
keywords: AML; clinical trials; molecular therapy; monoclonal antibodies; multikinase inhibitors